These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21827995)

  • 1. Moxifloxacin-dependent Torsades de Pointes.
    Tiryakioğlu SK; Tiryakioğlu O; Aktürk F; Mehmetoğlu E; Kumbay E
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):560-2. PubMed ID: 21827995
    [No Abstract]   [Full Text] [Related]  

  • 2. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
    Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
    Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin-induced torsades de pointes.
    Sherazi S; DiSalle M; Daubert JP; Shah AH
    Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
    Frothingham R
    Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based review of moxifloxacin.
    O'Brien TP
    Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
    [No Abstract]   [Full Text] [Related]  

  • 7. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions.
    Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin does increase the corrected QT interval.
    White CM; Grant EM; Quintiliani R
    Clin Infect Dis; 2001 Oct; 33(8):1441-4. PubMed ID: 11565091
    [No Abstract]   [Full Text] [Related]  

  • 9. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
    Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of extensively drug-resistant tuberculosis.
    Aggarwal D; Mohapatra PR; Janmeja AK
    Lancet; 2009 Jan; 373(9657):26-7; author reply 27-8. PubMed ID: 19121714
    [No Abstract]   [Full Text] [Related]  

  • 12. Multidrug-resistant viridans streptococcus (MDRVS) osteomyelitis of the mandible successfully treated with moxifloxacin.
    Ang JY; Asmar BI
    South Med J; 2008 May; 101(5):539-40. PubMed ID: 18414152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
    Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration and accumulation of moxifloxacin in uterine tissue.
    Stass H; Kubitza D; Aydeniz B; Wallwiener D; Halabi A; Gleiter C
    Int J Gynaecol Obstet; 2008 Aug; 102(2):132-6. PubMed ID: 18501909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Moxifloxacin clinical and microbiological efficacy in therapy of infectious endocarditis].
    Beloborodova NV; Popov DA; Bachinskaia EN; Sedrakian AR; Vostrikova TIu
    Antibiot Khimioter; 2006; 51(9-10):33-9. PubMed ID: 18030789
    [No Abstract]   [Full Text] [Related]  

  • 16. [Investigation of moxifloxacin, a new antimicrobial of the fluoroquinolone group in Russia].
    Iakovlev VS; Iakovlev VP
    Antibiot Khimioter; 2007; 52(6):28-35. PubMed ID: 18476472
    [No Abstract]   [Full Text] [Related]  

  • 17. [Abstracts of the 6th Moxifloxacin Research Workshop, March 1-2, 2007, Leverkusen, Germany].
    Infection; 2007 Aug; 35 Suppl 1():i-x, 4-73. PubMed ID: 18183639
    [No Abstract]   [Full Text] [Related]  

  • 18. [Abstracts of 8th Moxifloxacin Research Workshop. November 17-18, 2012. Leverkusen, Germany].
    Infection; 2012 Aug; 40 Suppl 1():1-71. PubMed ID: 22936293
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies.
    Baas T; Gräfe K; Khawaja A; Dössel O
    Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():3796-9. PubMed ID: 22255166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome.
    Chiba K; Sugiyama A; Hagiwara T; Takahashi S; Takasuna K; Hashimoto K
    Eur J Pharmacol; 2004 Feb; 486(2):189-200. PubMed ID: 14975708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.